Turning Point Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPTX research report →
Companywww.tptherapeutics.com
Turning Point Therapeutics, Inc. , a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
- CEO
- Athena Maria Countouriotis
- IPO
- 2019
- Employees
- 267
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -13.03
- P/S
- 0.00
- P/B
- 3.23
- EV/EBITDA
- 1.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -767.30%
- Net Margin
- -767.30%
- ROE
- -22.92%
- ROIC
- -24.64%
Growth & Income
- Revenue
- $30.83M · 23.32%
- Net Income
- $-236,551,000 · -50.39%
- EPS
- $-5.79 · -50.39%
- Op Income
- $-236,551,000
- FCF YoY
- -85.96%
Performance & Tape
- Beta
- -0.19
Get TickerSpark's AI analysis on TPTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 22 | Nicholson Garry A | sell | 23,400 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Machado Patrick | sell | 30,000 |
| Aug 17, 22 | George Simeon | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 30,000 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Bodem Barbara W. | sell | 14,995 |
Our TPTX Coverage
We haven't published any research on TPTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TPTX Report →